Evidence map›Paper›PMID 40237453›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Performance of 2 Finger-Stick Blood Tests to Triage Adults With Symptoms of Pulmonary Tuberculosis: A Prospective Multisite Diagnostic Accuracy Study.

Jayne S Sutherland, Gian D van der Spuy, Jane A Shaw, Tracy Richardson, Elisa M Tjon Kon Fat, Awa Gindeh, Olumuyiwa Owolabi, Nguyen Thuy Thuong Thuong, Le Hong Van, Nguyen Hoang Van and 20 more

Abstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Jayne S SutherlandVaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.ORCID 0000-0002-7083-4997
Gian D van der SpuyDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Jane A ShawDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-9893-3073
Tracy RichardsonDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Elisa M Tjon Kon FatDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Awa GindehVaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.
Olumuyiwa OwolabiVaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.
Nguyen Thuy Thuong ThuongOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Le Hong VanOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Nguyen Hoang VanOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.ORCID 0000-0002-1571-321X
Dang Thi Thanh ThaoOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.ORCID 0009-0004-2227-5416
Harriet Mayanja-KizzaDepartment of Medicine, Makerere University, Kampala, Uganda.
Mary NserekoDepartment of Medicine, Makerere University, Kampala, Uganda.
AnnRitah NamugangaDepartment of Medicine, Makerere University, Kampala, Uganda.
Sophie NalukwagoDepartment of Medicine, Makerere University, Kampala, Uganda.ORCID 0009-0002-9928-4578
John BelisleMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Emmanuel MoreauFIND, Geneva, Switzerland.
Adam Penn-NicholsonFIND, Geneva, Switzerland.ORCID 0000-0002-1883-0059
Guy ThwaitesOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Jill WinterCatalysis Foundation, Berkeley, California, USA.
Hazel M DockrellDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Thomas J ScribaDivision of Immunology, Department of Pathology, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Kim StanleyDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-2030-7275
Bronwyn SmithDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Novel N ChegouDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Stephanus T MalherbeDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-7563-8231
Annemieke GelukDepartment of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-8555-2872
Paul CorstjensDepartment of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Gerhard WalzlDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0003-2487-125X
TrENDx-TB consortium

Funding

Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)U01AI152075 · NIAID · STELLENBOSCH UNIVERSITY · PI BELISLE, JOHN T, SUTHERLAND, JAYNE · 2020 to 2025
$7.1M
European & Developing Countries Clinical Trials Partnership RIA2018D-2499Gates Foundation INV-023825NIAID NIH HHS U01 AI152075NIH HHS U01AI152075South African National Research Foundation SANRF86535
6 · The paper itself

Abstract

backgroundNon-sputum-based, point-of-care triage tests for pulmonary tuberculosis could enhance tuberculosis diagnostic programs. We assessed the diagnostic accuracy of 2 finger-stick blood tests: the Cepheid 3 gene host-response cartridge (Xpert-HR), which measures 3 host messenger RNA transcripts, and the 3-host protein multibiomarker test (MBT).

methodsWe performed a prospective diagnostic accuracy study of consecutive participants with symptoms compatible with pulmonary tuberculosis in The Gambia, South Africa, Uganda, and Vietnam. A composite reference standard for active pulmonary tuberculosis incorporated chest radiography, symptom resolution, and sputum microbiological test results. A training-test set approach was used to evaluate test cutoff specificities at 90% sensitivity.

resultsBetween 1 November 2020 and 1 May 2023, we screened 1262 participants aged 12-70 years with cough lasting >2 weeks and another symptom suggestive of tuberculosis. Of those who were classifiable by reference tests, 1154 participants had evaluable Xpert-HR results and 961 had evaluable MBT results. Xpert-HR had an area under the receiver operating characteristic (AUROC) curve of 0.92 at a cutoff of -1.275 or below, with a sensitivity of 92.8%, specificity of 62.5%, positive predictive value of 47.9%, and negative predictive value of 95.9%. The MBT had an AUROC of 0.91 at a cutoff of ≥0.42, with a sensitivity of 91.4%, specificity of 73.2%, positive predictive value of 52.0%, and negative predictive value of 96.4%.

conclusionsOur results show that both Xpert-HR and the MBT are promising non-sputum-based point-of-care tests. The MBT met the World Health Organization target product profile for a triage test, which suggests it should be further developed.

Indexed as

Hematologic TestsTriageTuberculosis, PulmonaryAdolescentAdultAgedChildFemaleGambiaHumansMaleMiddle AgedPoint-of-Care TestingProspective StudiesSensitivity and SpecificitySouth AfricaBiomarkersdiagnosispoint-of-caretriagetuberculosis

Identifiers

PMID40237453
PMCPMC12596368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.